<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25673440</article-id><article-id pub-id-type="pmc">4836241</article-id><article-id pub-id-type="publisher-id">CMJ-128-427</article-id><article-id pub-id-type="doi">10.4103/0366-6999.151057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of Gonadotropin Releasing Hormone Agonist Administration to Endometriosis Patients: A Randomized, Double-blind, Blank- and Tibolone-controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ji-Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Hong-Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Guo-Hua</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Gynecology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China</aff><aff id="aff2"><label>2</label>Department of Gynecology, Jintan Hospital Affiliated to Jiangsu University, Jintan, Jiangsu 213200, China</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hong-Yan Gao, Department of Gynecology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, China E-Mail: <email xlink:href="649891742@qq.com">649891742@qq.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>2</month><year>2015</year></pub-date><volume>128</volume><issue>4</issue><fpage>427</fpage><lpage>432</lpage><history><date date-type="received"><day>19</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: Â© 2015 Chinese Medical Journal</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3896" xml_f="3907" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3918" xml_f="4420" txt_i="23" txt_f="525">As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal women. But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by gonadotropin releasing hormone agonist (GnRH-a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in endometriosis (EMS) patients, with postoperative GnRH-a treatment.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4451" xml_f="4459" txt_i="527" txt_f="535">Methods:</offsets></title><p><offsets xml_i="4470" xml_f="5168" txt_i="536" txt_f="1234">Ninety EMS ovarian cyst women with postoperative GnRH-a administration were enrolled in the study, and were randomly divided into Kuntai group, Tibolone group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first GnRH-a injection, while Tibolone 2.5 mg qd, po for 12 weeks in Tibolone group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. Liver and renal functions, lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and Tibolone groups was recorded.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5199" xml_f="5207" txt_i="1236" txt_f="1244">Results:</offsets></title><p><offsets xml_i="5218" xml_f="5313" txt_i="1245" txt_f="1340">(1) Before GnRH-a therapy, the baseline parameter results were comparable in the three groups (</offsets><italic><offsets xml_i="5321" xml_f="5322" txt_i="1340" txt_f="1341">P</offsets></italic><offsets xml_i="5331" xml_f="5453" txt_i="1341" txt_f="1460"> &gt; 0.05). (2) After GnRH-a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (</offsets><italic><offsets xml_i="5461" xml_f="5462" txt_i="1460" txt_f="1461">P</offsets></italic><offsets xml_i="5471" xml_f="5492" txt_i="1461" txt_f="1479"> &lt; 0.05). At the 4</offsets><sup><offsets xml_i="5497" xml_f="5499" txt_i="1479" txt_f="1481">th</offsets></sup><offsets xml_i="5505" xml_f="5644" txt_i="1481" txt_f="1614"> week after GnRH-a therapy, KMI and hot flash/sweating score results were as follows: Control group &gt; Kuntai group &gt; Tibolone group (</offsets><italic><offsets xml_i="5652" xml_f="5653" txt_i="1614" txt_f="1615">P</offsets></italic><offsets xml_i="5662" xml_f="5683" txt_i="1615" txt_f="1633"> &lt; 0.05); at the 8</offsets><sup><offsets xml_i="5688" xml_f="5690" txt_i="1633" txt_f="1635">th</offsets></sup><offsets xml_i="5696" xml_f="5703" txt_i="1635" txt_f="1642"> and 12</offsets><sup><offsets xml_i="5708" xml_f="5710" txt_i="1642" txt_f="1644">th</offsets></sup><offsets xml_i="5716" xml_f="5847" txt_i="1644" txt_f="1775"> week after GnRH-a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (</offsets><italic><offsets xml_i="5855" xml_f="5856" txt_i="1775" txt_f="1776">P</offsets></italic><offsets xml_i="5865" xml_f="5958" txt_i="1776" txt_f="1866"> &lt; 0.05), and no significant difference was identified between Kuntai and Tibolone group (</offsets><italic><offsets xml_i="5966" xml_f="5967" txt_i="1866" txt_f="1867">P</offsets></italic><offsets xml_i="5976" xml_f="6122" txt_i="1867" txt_f="2010"> &gt; 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (</offsets><italic><offsets xml_i="6130" xml_f="6131" txt_i="2010" txt_f="2011">P</offsets></italic><offsets xml_i="6140" xml_f="6344" txt_i="2011" txt_f="2212"> &gt; 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (</offsets><italic><offsets xml_i="6352" xml_f="6353" txt_i="2212" txt_f="2213">P</offsets></italic><offsets xml_i="6362" xml_f="6471" txt_i="2213" txt_f="2319"> &lt; 0.05). After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (</offsets><italic><offsets xml_i="6479" xml_f="6480" txt_i="2319" txt_f="2320">P</offsets></italic><offsets xml_i="6489" xml_f="6548" txt_i="2320" txt_f="2376"> &lt; 0.05), while FSH and LH levels were obviously lower (</offsets><italic><offsets xml_i="6556" xml_f="6557" txt_i="2376" txt_f="2377">P</offsets></italic><offsets xml_i="6566" xml_f="6698" txt_i="2377" txt_f="2506"> &lt; 0.05). (5) The incidence of vaginal bleeding, breast distending pain in Tibolne group was obviously higher than Kuntai group (</offsets><italic><offsets xml_i="6706" xml_f="6707" txt_i="2506" txt_f="2507">P</offsets></italic><offsets xml_i="6716" xml_f="6729" txt_i="2507" txt_f="2517"> &lt; 0. 05).</offsets></p></sec><sec id="st4"><title><offsets xml_i="6760" xml_f="6772" txt_i="2519" txt_f="2531">Conclusions:</offsets></title><p><offsets xml_i="6783" xml_f="7038" txt_i="2532" txt_f="2787">Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative GnRH-a administration to EMS patients, although its clinical effect might be a few weeks later than Tibolone. Kuntai capsule might be a little safer than Tibolone tablet.</offsets></p></sec></abstract><kwd-group><kwd>Endometriosis</kwd><kwd>Kuntai Capsule</kwd><kwd>Kupperman Menopausal Index</kwd><kwd>Peri-menopausal Symptoms</kwd><kwd>Tibolone</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="7292" xml_f="7293" txt_i="2796" txt_f="2797">I</offsets><sc><offsets xml_i="7297" xml_f="7308" txt_i="2797" txt_f="2808">NTRODUCTION</offsets></sc></title><p><offsets xml_i="7324" xml_f="7564" txt_i="2809" txt_f="3049">Endometriosis (EMS) is one of the most common gynecological disorders in women of reproductive age, leading to symptoms such as dysmenorrhea, pelvic pain, and menorrhagia, as well as an association with significant impairment of fertility.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="7597" xml_f="7598" txt_i="3049" txt_f="3050">1</offsets></xref><xref rid="ref2" ref-type="bibr"><offsets xml_i="7638" xml_f="7639" txt_i="3050" txt_f="3051">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="7679" xml_f="7680" txt_i="3051" txt_f="3052">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="7720" xml_f="7721" txt_i="3052" txt_f="3053">4</offsets></xref><offsets xml_i="7728" xml_f="8014" txt_i="3053" txt_f="3339">] The postoperative recurrence problem of EMS has plagued gynecologists and patients all the time. The application of gonadotropin releasing hormone agonist (GnRH-a) is very important for reducing EMS recurrence, and it has been most commonly used for the prevention of EMS recurrence.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="8047" xml_f="8048" txt_i="3339" txt_f="3340">5</offsets></xref><offsets xml_i="8055" xml_f="8289" txt_i="3340" txt_f="3574">] However, the employment of GnRH-a could reduce the estrogen level, leading to some peri-menopausal symptoms such as hot flash, colpoxerosis, sexual hypoactivity, and bone loss, which hinders its long-term and extensive application.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="8322" xml_f="8323" txt_i="3574" txt_f="3575">6</offsets></xref><offsets xml_i="8330" xml_f="8474" txt_i="3575" txt_f="3719">] As peri-menopausal symptoms have a seriously negative impact on life quality, some of these patients try to avoid or discontinue such therapy.</offsets></p><p><offsets xml_i="8481" xml_f="8766" txt_i="3720" txt_f="4005">Hormone based âadd-back therapy,â was regarded as a good solution to the peri-menopausal symptoms. But long-term use of hormone might lead to liver damage, venous thrombosis, vascular diseases, and increase the risk of endometrial cancer, ovarian cancer, and breast cancer, and so on.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="8799" xml_f="8800" txt_i="4005" txt_f="4006">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="8840" xml_f="8841" txt_i="4006" txt_f="4007">8</offsets></xref><offsets xml_i="8848" xml_f="9107" txt_i="4007" txt_f="4266">] As a result, seeking an effective and safe alternative drug for the add-back therapy has become a priority task, which should be immediately performed. Meanwhile, the interest in traditional Chinese herbal preparations such as Kuntai capsule is increasing.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="9140" xml_f="9141" txt_i="4266" txt_f="4267">9</offsets></xref><offsets xml_i="9148" xml_f="9149" txt_i="4267" txt_f="4268">]</offsets></p><p><offsets xml_i="9156" xml_f="9646" txt_i="4269" txt_f="4759">Kuntai capsule is a kind of Chinese Traditional Medicine product, containing six kinds of Chinese medicine ingredients such as Radix Rehmanniae Preparata, Rhizoma Coptidis, Radix Paeoniae Alba, Donkey Hide Gelatin, Radix Scutellariae, Poria, with the effects of Ziyin/Nourishing Yin, reducing pathogenic fire, stabling mind, eliminating worries and regulating Yin and Yang, which could effectively relieve natural menopausal symptoms, and improve the life quality of peri-menopausal women.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="9680" xml_f="9682" txt_i="4759" txt_f="4761">10</offsets></xref><offsets xml_i="9689" xml_f="9835" txt_i="4761" txt_f="4907">] Many studies showed that, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal women, and had no apparent estrogenicity.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="9869" xml_f="9871" txt_i="4907" txt_f="4909">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="9912" xml_f="9914" txt_i="4909" txt_f="4911">11</offsets></xref><offsets xml_i="9921" xml_f="10505" txt_i="4911" txt_f="5495">] But it is still not clear whether Kuntai capsule has a similar effect with Tibolone on alleviating peri-menopausal symptoms induced by GnRH-a treatment, and what the safety profile of this capsule is, all these need to be confirmed by further studies. The aim of the present double-blind, randomized, blank- and Tibolone-controlled clinical study was to assess the efficacy and safety of Kuntai capsule and Tibolone on peri-menopausal symptoms induced by postoperative GnRH-a injection in EMS women, and to provide a new and safe alternative treatment option for âadd-back therapy.â</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="10558" xml_f="10559" txt_i="5497" txt_f="5498">M</offsets><sc><offsets xml_i="10563" xml_f="10569" txt_i="5498" txt_f="5504">ETHODS</offsets></sc></title><sec id="sec2-1"><title><offsets xml_i="10606" xml_f="10614" txt_i="5505" txt_f="5513">Subjects</offsets></title><p><offsets xml_i="10625" xml_f="11665" txt_i="5514" txt_f="6554">A total of 90 EMS ovarian cyst women with GnRH-a treatment after laparoscopic operation were recruited for the study in the Department of Gynecology, Third Affiliated Hospital of Soochow University and Jintan Hospital Affiliated to Jiangsu University (China) from April 2009 to December 2013. With the patientsâ informed consents to the study, they were randomly assigned to the Kuntai, Tibolone or Control group. Fifteen women were excluded from the study due to withdrawal of informed consent, failure for being followed-up, or protocol violations. At the end, 75 patientsâ data were included and analyzed, 25 patients in each group. All women with EMS ovarian cyst underwent laparoscopic surgery. Pathological examinations were performed in all cases, and subsequently confirmed by diagnostic norms. Any case without typical medical history, diagnostic norms, or surgery was not included in the study. According to the revised American Fertility Society classification of EMS in 1985, the EMS patients could be categorized to Stage III (</offsets><italic><offsets xml_i="11673" xml_f="11674" txt_i="6554" txt_f="6555">n</offsets></italic><offsets xml_i="11683" xml_f="11698" txt_i="6555" txt_f="6570"> = 13) and IV (</offsets><italic><offsets xml_i="11706" xml_f="11707" txt_i="6570" txt_f="6571">n</offsets></italic><offsets xml_i="11716" xml_f="11751" txt_i="6571" txt_f="6606"> = 12) in Kuntai group, Stage III (</offsets><italic><offsets xml_i="11759" xml_f="11760" txt_i="6606" txt_f="6607">n</offsets></italic><offsets xml_i="11769" xml_f="11784" txt_i="6607" txt_f="6622"> = 12) and IV (</offsets><italic><offsets xml_i="11792" xml_f="11793" txt_i="6622" txt_f="6623">n</offsets></italic><offsets xml_i="11802" xml_f="11839" txt_i="6623" txt_f="6660"> = 13) in Tibolone group, Stage III (</offsets><italic><offsets xml_i="11847" xml_f="11848" txt_i="6660" txt_f="6661">n</offsets></italic><offsets xml_i="11857" xml_f="11872" txt_i="6661" txt_f="6676"> = 13) and IV (</offsets><italic><offsets xml_i="11880" xml_f="11881" txt_i="6676" txt_f="6677">n</offsets></italic><offsets xml_i="11890" xml_f="12391" txt_i="6677" txt_f="7175"> = 12) in Control group. The main exclusion criteria were as follows: (1) Pregnancy, (2) current or past history of malignancy, or current contraindication to either goserelin, Kuntai or Tibolone as documented in the summary of product characteristics for each product, (3) hormone therapy in the last 4 weeks before study entry, or usage of any drug, nutritional supplement, food or Traditional Chinese Medicine against climacteric complaints, (4) psychoactive drugs, (5) body mass index &gt; 28 kg/m</offsets><sup><offsets xml_i="12396" xml_f="12397" txt_i="7175" txt_f="7176">2</offsets></sup><offsets xml_i="12403" xml_f="13132" txt_i="7176" txt_f="7905">, (6) irregular gynecological bleeding in the last 4 weeks before medication start, cervical smear examination with any intraepithelial pathologic change (i.e. atypical squamous cell of undetermined significance), (7) cancer, (8) severe or current disease which could interfere with the climacteric complaints, or the actual or expected treatment which could interfere with the study objectives, (9) liver damage, severe diabetes, hypertension medical history, or thromboembolic disease, (10) drug abuse or alcohol addiction, (11) participation in another clinical trial, etc. These three group patients were followed-up for 12 weeks; and women who had treatment interruption less than 12 weeks would be ruled out from the study.</offsets></p><p><offsets xml_i="13139" xml_f="13424" txt_i="7906" txt_f="8191">The study design was approved by the Institutional Review Board at the Third Affiliated Hospital of Soochow University and got the permission of the local ethics committee. Informed consent and detailed information of the study were obtained from all participants prior to the therapy.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="13458" xml_f="13468" txt_i="8193" txt_f="8203">Treatments</offsets></title><p><offsets xml_i="13479" xml_f="14693" txt_i="8204" txt_f="9418">All patients were treated with GnRH-a (Zoladex: Goserelin Injection, Astrazeneca UK Limited) 1 week after laparoscopic ovarian cyst removal surgery. 3.6 mg GnRH-a was subcutaneously injected into all the patients every 4 weeks totally three times. In the same day with GnRH-a injection, Kuntai group was provided with oral Kuntai capsules (Guiyang Xintian Pharmaceutical Co. Ltd., State Medical Approval number: Z20000083; 4 capsules tid, po, half an hour after meal for 12 weeks), Tibolone group with oral Tibolone tablet (Nanjing Organon Pharmaceutical Co. Ltd. Product, Approval number: H20051085; 2.5 mg qd,po for 12 weeks), while Control group without any drug addition during the GnRH-a therapy and follow-up period. We took the date of the first GnRH-a injection as 0 week. The follow-up visit of the patients was carried out for 12 weeks as once every 4 weeks. The first visit began at 4 weeks after the first GnRH-a injection. Patients, who discontinued therapy within 12 weeks, used other hormonal drugs, or took nonhormonal drugs (including nutrition), or food which might interfere with symptoms, or used any hypnotic, sedative, and antidepressant drugs, were all removed from the statistical analysis.</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="14727" xml_f="14759" txt_i="9420" txt_f="9452">Evaluation and observation index</offsets></title><p><bold><offsets xml_i="14776" xml_f="14802" txt_i="9453" txt_f="9479">Kupperman menopausal index</offsets></bold></p><p><offsets xml_i="14816" xml_f="14974" txt_i="9480" txt_f="9638">The modified Kupperman menopausal index (KMI) is an internationally recognized and validated scale for the quantitative determination of menopausal symptoms.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="15007" xml_f="15008" txt_i="9638" txt_f="9639">9</offsets></xref><offsets xml_i="15015" xml_f="15346" txt_i="9639" txt_f="9967">] The modified KMI consists of 11 items, including hot flash/sweating, paresthesia, insomnia, nervousness, melancholia, vertigo, fatigue, arthralgia, headache, palpitation, and formication. Scores of KMI ranging from 15 to 20, 21â35, and &gt;35 were used to rate the degree of severity as mild, moderate, and severe, respectively.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="15380" xml_f="15382" txt_i="9967" txt_f="9969">12</offsets></xref><offsets xml_i="15389" xml_f="15437" txt_i="9969" txt_f="10017">] The patientsâ KMI scores were recorded at 0, 4</offsets><sup><offsets xml_i="15442" xml_f="15444" txt_i="10017" txt_f="10019">th</offsets></sup><offsets xml_i="15450" xml_f="15453" txt_i="10019" txt_f="10022">, 8</offsets><sup><offsets xml_i="15458" xml_f="15460" txt_i="10022" txt_f="10024">th</offsets></sup><offsets xml_i="15466" xml_f="15474" txt_i="10024" txt_f="10032">, and 12</offsets><sup><offsets xml_i="15479" xml_f="15481" txt_i="10032" txt_f="10034">th</offsets></sup><offsets xml_i="15487" xml_f="15545" txt_i="10034" txt_f="10092"> week after the GnRH-a therapy and analyzed statistically.</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="15579" xml_f="15604" txt_i="10094" txt_f="10119">Hot flash/sweating scores</offsets></title><p><offsets xml_i="15615" xml_f="15668" txt_i="10120" txt_f="10173">The hot flash/sweating scores of the patients at 0, 4</offsets><sup><offsets xml_i="15673" xml_f="15675" txt_i="10173" txt_f="10175">th</offsets></sup><offsets xml_i="15681" xml_f="15684" txt_i="10175" txt_f="10178">, 8</offsets><sup><offsets xml_i="15689" xml_f="15691" txt_i="10178" txt_f="10180">th</offsets></sup><offsets xml_i="15697" xml_f="15705" txt_i="10180" txt_f="10188">, and 12</offsets><sup><offsets xml_i="15710" xml_f="15712" txt_i="10188" txt_f="10190">th</offsets></sup><offsets xml_i="15718" xml_f="15790" txt_i="10190" txt_f="10262"> week after the GnRH-a therapy were recorded and analyzed statistically.</offsets></p></sec><sec id="sec2-5"><title><offsets xml_i="15824" xml_f="15849" txt_i="10264" txt_f="10289">Liver and renal functions</offsets></title><p><offsets xml_i="15860" xml_f="15914" txt_i="10290" txt_f="10344">Liver and renal function was examined initially and 12</offsets><sup><offsets xml_i="15919" xml_f="15921" txt_i="10344" txt_f="10346">th</offsets></sup><offsets xml_i="15927" xml_f="16242" txt_i="10346" txt_f="10661"> week after the GnRH-a treatment. Liver function referred to glutamic-pyruvic transaminase (alanine transaminase [ALT]) and glutamic oxalacetic transaminase (aspartate transaminase [AST]), and renal function was based on blood urea nitrogen (BUN) and creatinine (Cr). All data collected were analyzed statistically.</offsets></p></sec><sec id="sec2-6"><title><offsets xml_i="16276" xml_f="16289" txt_i="10663" txt_f="10676">Lipid profile</offsets></title><p><offsets xml_i="16300" xml_f="16541" txt_i="10677" txt_f="10918">Lipid profile, including total cholesterol (CHOL), triglyceride (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), were tested before and 12 weeks after the GnRH-a therapy. All data collected were analyzed statistically.</offsets></p></sec><sec id="sec2-7"><title><offsets xml_i="16575" xml_f="16599" txt_i="10920" txt_f="10944">Serum sex hormone levels</offsets></title><p><offsets xml_i="16610" xml_f="16880" txt_i="10945" txt_f="11215">The following serum hormones were measured: 17Î²-estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). The hormone data based on venous blood examination were collected before and 12 weeks after GnRH-a therapy, and were analyzed statistically.</offsets></p></sec><sec id="sec2-8"><title><offsets xml_i="16914" xml_f="16935" txt_i="11217" txt_f="11238">Endometrial thickness</offsets></title><p><offsets xml_i="16946" xml_f="17138" txt_i="11239" txt_f="11431">Endometrial thickness was detected by B ultrasound (PT380 Color Doppler Ultrasound Diagnosis System, Toshiba, Japan) before and 12 weeks after GnRH-a treatment, and was analyzed statistically.</offsets></p></sec><sec id="sec2-9"><title><offsets xml_i="17172" xml_f="17195" txt_i="11433" txt_f="11456">Adverse reaction events</offsets></title><p><offsets xml_i="17206" xml_f="17488" txt_i="11457" txt_f="11739">The adverse reaction events of the patients during the therapy were recorded, including anaphylaxis (rash, pruritus, dyspnea), headache, dizziness, nausea, emesis, abdominal discomfort, weight increasing, breast distending pain, and vaginal bleeding or spotting of unknown etiology.</offsets></p></sec><sec id="sec2-10"><title><offsets xml_i="17523" xml_f="17543" txt_i="11741" txt_f="11761">Statistical analysis</offsets></title><p><offsets xml_i="17554" xml_f="17912" txt_i="11762" txt_f="12120">Statistical analysis was performed using SPSS version 13.0 software package (SPSS Inc., Chicago, IL, USA). Measurement data were presented as mean Â± standard deviation (SD), using analysis of variance for different groups. If statistical significance was identified, the further Q-test would be performed for two-two comparison. Count data were analyzed by Ï</offsets><sup><offsets xml_i="17917" xml_f="17918" txt_i="12120" txt_f="12121">2</offsets></sup><offsets xml_i="17924" xml_f="17951" txt_i="12121" txt_f="12148">-test, if the multi-group Ï</offsets><sup><offsets xml_i="17956" xml_f="17957" txt_i="12148" txt_f="12149">2</offsets></sup><offsets xml_i="17963" xml_f="17999" txt_i="12149" txt_f="12185">-test was significant, the further Ï</offsets><sup><offsets xml_i="18004" xml_f="18005" txt_i="12185" txt_f="12186">2</offsets></sup><offsets xml_i="18011" xml_f="18081" txt_i="12186" txt_f="12256">-test would be performed for two-two comparison. A two-sided value of </offsets><italic><offsets xml_i="18089" xml_f="18090" txt_i="12256" txt_f="12257">P</offsets></italic><offsets xml_i="18099" xml_f="18157" txt_i="12257" txt_f="12312"> &lt; 0.05 was considered to be statistically significant.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="18216" xml_f="18217" txt_i="12315" txt_f="12316">R</offsets><sc><offsets xml_i="18221" xml_f="18227" txt_i="12316" txt_f="12322">ESULTS</offsets></sc></title><sec id="sec2-11"><title><offsets xml_i="18265" xml_f="18281" txt_i="12323" txt_f="12339">Study population</offsets></title><p><offsets xml_i="18292" xml_f="18727" txt_i="12340" txt_f="12775">A total of 90 patients was involved in this study and was randomized into three groups. Among these populations, 6 patients dropped out prematurely due to withdrawal of informed consent after baseline or being lost to be followed-up. Another 9 women were excluded from the final statistical analyses due to drug or food consumption which might interfere with the peri-menopausal symptoms (noncompliance that were detailed previously).[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="18761" xml_f="18763" txt_i="12775" txt_f="12777">13</offsets></xref><offsets xml_i="18770" xml_f="19028" txt_i="12777" txt_f="13035">] The remaining 75 women were included in the per-protocol analysis (25 in each group). Patient's characteristics at baseline (age, body mass index, ratio of waist/hip circumference, blood pressure, heart rate, etc.) were comparable in all treatment groups [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="19060" xml_f="19067" txt_i="13035" txt_f="13042">Table 1</offsets></xref><offsets xml_i="19074" xml_f="19154" txt_i="13042" txt_f="13122">]. No significant difference among all indexes was observed in the three groups.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="19202" xml_f="19209" txt_i="13123" txt_f="13130">Table 1</offsets></label><caption><p><offsets xml_i="19229" xml_f="19293" txt_i="13130" txt_f="13194">Baseline characteristics of the patients included in the trial (</offsets><italic><offsets xml_i="19301" xml_f="19302" txt_i="13194" txt_f="13195">n</offsets></italic><offsets xml_i="19311" xml_f="19317" txt_i="13195" txt_f="13201"> = 25)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="19420" xml_f="19435" txt_i="13202" txt_f="13217">Characteristics</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="19483" xml_f="19489" txt_i="13217" txt_f="13223">Kuntai</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="19537" xml_f="19545" txt_i="13223" txt_f="13231">Tibolone</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="19593" xml_f="19600" txt_i="13231" txt_f="13238">Control</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19670" xml_f="19681" txt_i="13238" txt_f="13249">Age (years)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19729" xml_f="19741" txt_i="13250" txt_f="13262">29.84 Â± 4.26</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19789" xml_f="19801" txt_i="13263" txt_f="13275">30.36 Â± 4.71</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19849" xml_f="19861" txt_i="13276" txt_f="13288">30.64 Â± 4.71</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19916" xml_f="19925" txt_i="13289" txt_f="13298">BMI (kg/m</offsets><sup><offsets xml_i="19930" xml_f="19931" txt_i="13298" txt_f="13299">2</offsets></sup><offsets xml_i="19937" xml_f="19938" txt_i="13299" txt_f="13300">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19986" xml_f="19998" txt_i="13301" txt_f="13313">22.32 Â± 1.77</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20046" xml_f="20058" txt_i="13314" txt_f="13326">22.28 Â± 1.67</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20106" xml_f="20118" txt_i="13327" txt_f="13339">22.80 Â± 1.98</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20173" xml_f="20196" txt_i="13340" txt_f="13363">Waist/hip circumference</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20244" xml_f="20255" txt_i="13364" txt_f="13375">0.84 Â± 0.05</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20303" xml_f="20314" txt_i="13376" txt_f="13387">0.83 Â± 0.06</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20362" xml_f="20374" txt_i="13388" txt_f="13400">0.83 Â± 0. 06</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20429" xml_f="20453" txt_i="13401" txt_f="13425">Systolic pressure (mmHg)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20501" xml_f="20514" txt_i="13426" txt_f="13439">114.28 Â± 8.72</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20562" xml_f="20575" txt_i="13440" txt_f="13453">115.80 Â± 7.20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20623" xml_f="20636" txt_i="13454" txt_f="13467">115.68 Â± 7.53</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20691" xml_f="20716" txt_i="13468" txt_f="13493">Diastolic pressure (mmHg)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20764" xml_f="20776" txt_i="13494" txt_f="13506">72.96 Â± 5.65</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20824" xml_f="20836" txt_i="13507" txt_f="13519">74.16 Â± 4.75</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20884" xml_f="20896" txt_i="13520" txt_f="13532">75.76 Â± 4.80</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20951" xml_f="20973" txt_i="13533" txt_f="13555">Heart rate (times/min)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="21021" xml_f="21033" txt_i="13556" txt_f="13568">76.68 Â± 3.25</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="21081" xml_f="21093" txt_i="13569" txt_f="13581">76.36 Â± 3.28</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="21141" xml_f="21153" txt_i="13582" txt_f="13594">77.08 Â± 3.13</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="21203" xml_f="21224" txt_i="13595" txt_f="13616">BMI: Body mass index.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-12"><title><offsets xml_i="21295" xml_f="21327" txt_i="13618" txt_f="13650">Kupperman menopausal index score</offsets></title><p><offsets xml_i="21338" xml_f="21414" txt_i="13651" txt_f="13727">Kupperman menopausal index scores of the three groups were evaluated at 0, 4</offsets><sup><offsets xml_i="21419" xml_f="21421" txt_i="13727" txt_f="13729">th</offsets></sup><offsets xml_i="21427" xml_f="21430" txt_i="13729" txt_f="13732">, 8</offsets><sup><offsets xml_i="21435" xml_f="21437" txt_i="13732" txt_f="13734">th</offsets></sup><offsets xml_i="21443" xml_f="21451" txt_i="13734" txt_f="13742">, and 12</offsets><sup><offsets xml_i="21456" xml_f="21458" txt_i="13742" txt_f="13744">th</offsets></sup><offsets xml_i="21464" xml_f="21581" txt_i="13744" txt_f="13861"> week after the GnRH-a therapy. No significant difference was observed among the three groups before GnRH-a therapy (</offsets><italic><offsets xml_i="21589" xml_f="21590" txt_i="13861" txt_f="13862">P</offsets></italic><offsets xml_i="21599" xml_f="21776" txt_i="13862" txt_f="14036"> &gt; 0.05). In all the three groups, the KMI scores were identified to have a significant increase after GnRH-a therapy in comparison to the pretherapeutic level respectively (</offsets><italic><offsets xml_i="21784" xml_f="21785" txt_i="14036" txt_f="14037">P</offsets></italic><offsets xml_i="21794" xml_f="21815" txt_i="14037" txt_f="14055"> &lt; 0.05). At the 4</offsets><sup><offsets xml_i="21820" xml_f="21822" txt_i="14055" txt_f="14057">th</offsets></sup><offsets xml_i="21828" xml_f="21946" txt_i="14057" txt_f="14169"> week after GnRH-a therapy, the KMI score result was as follows: Control group &gt; Kuntai group &gt; Tibolone group (</offsets><italic><offsets xml_i="21954" xml_f="21955" txt_i="14169" txt_f="14170">P</offsets></italic><offsets xml_i="21964" xml_f="21985" txt_i="14170" txt_f="14188"> &lt; 0.05); at the 8</offsets><sup><offsets xml_i="21990" xml_f="21992" txt_i="14188" txt_f="14190">th</offsets></sup><offsets xml_i="21998" xml_f="22005" txt_i="14190" txt_f="14197"> and 12</offsets><sup><offsets xml_i="22010" xml_f="22012" txt_i="14197" txt_f="14199">th</offsets></sup><offsets xml_i="22018" xml_f="22125" txt_i="14199" txt_f="14306"> week after GnRH-a therapy, KMI score of control group was significantly higher than the other two groups (</offsets><italic><offsets xml_i="22133" xml_f="22134" txt_i="14306" txt_f="14307">P</offsets></italic><offsets xml_i="22143" xml_f="22232" txt_i="14307" txt_f="14393"> &lt; 0.05), but no significant difference was found between Kuntai and Tibolone groups (</offsets><italic><offsets xml_i="22240" xml_f="22241" txt_i="14393" txt_f="14394">P</offsets></italic><offsets xml_i="22250" xml_f="22289" txt_i="14394" txt_f="14430"> &gt; 0.05). The results were shown in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="22319" xml_f="22327" txt_i="14430" txt_f="14438">Figure 1</offsets></xref><offsets xml_i="22334" xml_f="22335" txt_i="14438" txt_f="14439">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="22376" xml_f="22384" txt_i="14440" txt_f="14448">Figure 1</offsets></label><caption><p><offsets xml_i="22404" xml_f="22512" txt_i="14448" txt_f="14556">Kupperman menopausal index score before and after gonadotropin releasing hormone agonist (GnRH-a) therapy. *</offsets><italic><offsets xml_i="22520" xml_f="22521" txt_i="14556" txt_f="14557">P</offsets></italic><offsets xml_i="22530" xml_f="22544" txt_i="14557" txt_f="14568"> &lt; 0.05, **</offsets><italic><offsets xml_i="22552" xml_f="22553" txt_i="14568" txt_f="14569">P</offsets></italic><offsets xml_i="22562" xml_f="22624" txt_i="14569" txt_f="14628"> &lt; 0.01 versus the same group at 0 week of GnRH-a therapy; </offsets><sup><offsets xml_i="22629" xml_f="22630" txt_i="14628" txt_f="14629">â </offsets></sup><italic><offsets xml_i="22644" xml_f="22645" txt_i="14629" txt_f="14630">P</offsets></italic><offsets xml_i="22654" xml_f="22716" txt_i="14630" txt_f="14689"> &lt; 0.05 versus Tibolone group 4 week after GnRH-a therapy; </offsets><sup><offsets xml_i="22721" xml_f="22722" txt_i="14689" txt_f="14690">â¡</offsets></sup><italic><offsets xml_i="22736" xml_f="22737" txt_i="14690" txt_f="14691">P</offsets></italic><offsets xml_i="22746" xml_f="22817" txt_i="14691" txt_f="14759"> &lt; 0.01 versus control group 8 week or 12 week after GnRH-a therapy.</offsets></p></caption><graphic xlink:href="CMJ-128-427-g001"></graphic></fig></sec><sec id="sec2-13"><title><offsets xml_i="22917" xml_f="22941" txt_i="14761" txt_f="14785">Hot flash/sweating score</offsets></title><p><offsets xml_i="22952" xml_f="23039" txt_i="14786" txt_f="14873">The hot flash/sweating scores of the patients in the three groups were recorded at 0, 4</offsets><sup><offsets xml_i="23044" xml_f="23046" txt_i="14873" txt_f="14875">th</offsets></sup><offsets xml_i="23052" xml_f="23055" txt_i="14875" txt_f="14878">, 8</offsets><sup><offsets xml_i="23060" xml_f="23062" txt_i="14878" txt_f="14880">th</offsets></sup><offsets xml_i="23068" xml_f="23076" txt_i="14880" txt_f="14888">, and 12</offsets><sup><offsets xml_i="23081" xml_f="23083" txt_i="14888" txt_f="14890">th</offsets></sup><offsets xml_i="23089" xml_f="23206" txt_i="14890" txt_f="15007"> week after the GnRH-a therapy. No significant difference was observed among the three groups before GnRH-a therapy (</offsets><italic><offsets xml_i="23214" xml_f="23215" txt_i="15007" txt_f="15008">P</offsets></italic><offsets xml_i="23224" xml_f="23394" txt_i="15008" txt_f="15175"> &gt; 0.05). For all the three groups, the hot flash/sweating scores increased significantly after GnRH-a therapy in comparison to the pretherapeutic level respectively (</offsets><italic><offsets xml_i="23402" xml_f="23403" txt_i="15175" txt_f="15176">P</offsets></italic><offsets xml_i="23412" xml_f="23433" txt_i="15176" txt_f="15194"> &lt; 0.05). At the 4</offsets><sup><offsets xml_i="23438" xml_f="23440" txt_i="15194" txt_f="15196">th</offsets></sup><offsets xml_i="23446" xml_f="23579" txt_i="15196" txt_f="15323"> week after GnRH-a therapy, the hot flash/sweating score result was as follows: Control group &gt; Kuntai group &gt; Tibolone group (</offsets><italic><offsets xml_i="23587" xml_f="23588" txt_i="15323" txt_f="15324">P</offsets></italic><offsets xml_i="23597" xml_f="23624" txt_i="15324" txt_f="15348"> &lt; 0.05); while at the 8</offsets><sup><offsets xml_i="23629" xml_f="23631" txt_i="15348" txt_f="15350">th</offsets></sup><offsets xml_i="23637" xml_f="23644" txt_i="15350" txt_f="15357"> and 12</offsets><sup><offsets xml_i="23649" xml_f="23651" txt_i="15357" txt_f="15359">th</offsets></sup><offsets xml_i="23657" xml_f="23783" txt_i="15359" txt_f="15485"> week after GnRH-a therapy, the hot flash/sweating score in control group was significantly higher than the other two groups (</offsets><italic><offsets xml_i="23791" xml_f="23792" txt_i="15485" txt_f="15486">P</offsets></italic><offsets xml_i="23801" xml_f="23895" txt_i="15486" txt_f="15577"> &lt; 0.05), but no significant difference was identified between Kuntai and Tibolone groups (</offsets><italic><offsets xml_i="23903" xml_f="23904" txt_i="15577" txt_f="15578">P</offsets></italic><offsets xml_i="23913" xml_f="23952" txt_i="15578" txt_f="15614"> &gt; 0.05). The results were shown in </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23982" xml_f="23990" txt_i="15614" txt_f="15622">Figure 2</offsets></xref><offsets xml_i="23997" xml_f="23998" txt_i="15622" txt_f="15623">.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="24039" xml_f="24047" txt_i="15624" txt_f="15632">Figure 2</offsets></label><caption><p><offsets xml_i="24067" xml_f="24167" txt_i="15632" txt_f="15732">Hot flash/sweating score before and after gonadotropin releasing hormone agonist (GnRH-a) therapy. *</offsets><italic><offsets xml_i="24175" xml_f="24176" txt_i="15732" txt_f="15733">P</offsets></italic><offsets xml_i="24185" xml_f="24199" txt_i="15733" txt_f="15744"> &lt; 0.05, **</offsets><italic><offsets xml_i="24207" xml_f="24208" txt_i="15744" txt_f="15745">P</offsets></italic><offsets xml_i="24217" xml_f="24279" txt_i="15745" txt_f="15804"> &lt; 0.01 versus the same group at 0 week of GnRH-a therapy; </offsets><sup><offsets xml_i="24284" xml_f="24285" txt_i="15804" txt_f="15805">â </offsets></sup><italic><offsets xml_i="24299" xml_f="24300" txt_i="15805" txt_f="15806">P</offsets></italic><offsets xml_i="24309" xml_f="24371" txt_i="15806" txt_f="15865"> &lt; 0.05 versus Tibolone group 4 week after GnRH-a therapy; </offsets><sup><offsets xml_i="24376" xml_f="24377" txt_i="15865" txt_f="15866">â¡</offsets></sup><italic><offsets xml_i="24391" xml_f="24392" txt_i="15866" txt_f="15867">P</offsets></italic><offsets xml_i="24401" xml_f="24472" txt_i="15867" txt_f="15935"> &lt; 0.01 versus Control group 8 week or 12 week after GnRH-a therapy.</offsets></p></caption><graphic xlink:href="CMJ-128-427-g002"></graphic></fig></sec><sec id="sec2-14"><title><offsets xml_i="24572" xml_f="24596" txt_i="15937" txt_f="15961">Liver and renal function</offsets></title><p><offsets xml_i="24607" xml_f="24966" txt_i="15962" txt_f="16321">No significant difference was identified among the three groups before treatment in the liver function referring to ALT (U/L) and AST (U/L), and the renal function including BUN (mmol/L) and Cr (Î¼mol/L). The liver and renal function changes after the therapy in each group had no significant difference in comparison to the pretherapeutic level respectively (</offsets><italic><offsets xml_i="24974" xml_f="24975" txt_i="16321" txt_f="16322">P</offsets></italic><offsets xml_i="24984" xml_f="24996" txt_i="16322" txt_f="16331"> &gt; 0.05).</offsets></p></sec><sec id="sec2-15"><title><offsets xml_i="25031" xml_f="25044" txt_i="16333" txt_f="16346">Lipid profile</offsets></title><p><offsets xml_i="25055" xml_f="25233" txt_i="16347" txt_f="16525">It was found that the lipid profile including CHOL (mg/dl), TG (mg/dl), LDL (mg/dl), and HDL (mg/dl) before treatment for all the three groups were of no significant difference (</offsets><italic><offsets xml_i="25241" xml_f="25242" txt_i="16525" txt_f="16526">P</offsets></italic><offsets xml_i="25251" xml_f="25369" txt_i="16526" txt_f="16641"> &gt; 0.05). There was no significant difference of lipid profile changes before and after the therapy in each group (</offsets><italic><offsets xml_i="25377" xml_f="25378" txt_i="16641" txt_f="16642">P</offsets></italic><offsets xml_i="25387" xml_f="25399" txt_i="16642" txt_f="16651"> &gt; 0.05).</offsets></p></sec><sec id="sec2-16"><title><offsets xml_i="25434" xml_f="25457" txt_i="16653" txt_f="16676">Serum sex hormone level</offsets></title><p><offsets xml_i="25468" xml_f="25659" txt_i="16677" txt_f="16868">The following sex hormones were measured: E2 (pg/ml), FSH (IU/L), and LH (IU/L). No significant difference was observed for these three hormones among the three groups before GnRH-a therapy (</offsets><italic><offsets xml_i="25667" xml_f="25668" txt_i="16868" txt_f="16869">P</offsets></italic><offsets xml_i="25677" xml_f="25841" txt_i="16869" txt_f="17030"> &gt; 0.05). However, for all the three groups, the posttherapeutic serum FSH, LH and E2 levels decreased significantly in comparison to the pretherapeutic levels (</offsets><italic><offsets xml_i="25849" xml_f="25850" txt_i="17030" txt_f="17031">P</offsets></italic><offsets xml_i="25859" xml_f="25981" txt_i="17031" txt_f="17150"> &lt; 0.05); in addition, after treatment, the E2 level in group Tibolone was obviously higher than the other two groups (</offsets><italic><offsets xml_i="25989" xml_f="25990" txt_i="17150" txt_f="17151">P</offsets></italic><offsets xml_i="25999" xml_f="26104" txt_i="17151" txt_f="17253"> &lt; 0.05), while the posttherapeutic FSH and LH levels were obviously lower than the other two groups (</offsets><italic><offsets xml_i="26112" xml_f="26113" txt_i="17253" txt_f="17254">P</offsets></italic><offsets xml_i="26122" xml_f="26260" txt_i="17254" txt_f="17389"> &lt; 0.05), and no significant difference was identified in the posttherapeutic E2, FSH and LH levels between Kuntai and Control groups (</offsets><italic><offsets xml_i="26268" xml_f="26269" txt_i="17389" txt_f="17390">P</offsets></italic><offsets xml_i="26278" xml_f="26317" txt_i="17390" txt_f="17426"> &gt; 0.05). All results were shown in </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="26347" xml_f="26355" txt_i="17426" txt_f="17434">Figure 3</offsets></xref><offsets xml_i="26362" xml_f="26363" txt_i="17434" txt_f="17435">.</offsets></p><fig id="F3" position="float"><label><offsets xml_i="26404" xml_f="26412" txt_i="17436" txt_f="17444">Figure 3</offsets></label><caption><p><offsets xml_i="26432" xml_f="26531" txt_i="17444" txt_f="17543">Serum sex hormone level before and after gonadotropin releasing hormone agonist (GnRH-a) therapy. *</offsets><italic><offsets xml_i="26539" xml_f="26540" txt_i="17543" txt_f="17544">P</offsets></italic><offsets xml_i="26549" xml_f="26563" txt_i="17544" txt_f="17555"> &lt; 0.05, **</offsets><italic><offsets xml_i="26571" xml_f="26572" txt_i="17555" txt_f="17556">P</offsets></italic><offsets xml_i="26581" xml_f="26639" txt_i="17556" txt_f="17611"> &lt; 0.01 versus the same group before GnRH-a treatment; </offsets><sup><offsets xml_i="26644" xml_f="26645" txt_i="17611" txt_f="17612">â </offsets></sup><italic><offsets xml_i="26659" xml_f="26660" txt_i="17612" txt_f="17613">P</offsets></italic><offsets xml_i="26669" xml_f="26681" txt_i="17613" txt_f="17622"> &lt; 0.05, </offsets><sup><offsets xml_i="26686" xml_f="26687" txt_i="17622" txt_f="17623">â </offsets></sup><sup><offsets xml_i="26698" xml_f="26699" txt_i="17623" txt_f="17624">â </offsets></sup><italic><offsets xml_i="26713" xml_f="26714" txt_i="17624" txt_f="17625">P</offsets></italic><offsets xml_i="26723" xml_f="26779" txt_i="17625" txt_f="17678"> &lt; 0.01 versus Tibolone group after GnRH-a treatment.</offsets></p></caption><graphic xlink:href="CMJ-128-427-g003"></graphic></fig></sec><sec id="sec2-17"><title><offsets xml_i="26879" xml_f="26900" txt_i="17680" txt_f="17701">Endometrial thickness</offsets></title><p><offsets xml_i="26911" xml_f="27011" txt_i="17702" txt_f="17802">Endometrial thickness was not significantly different among the three groups before GnRH-a therapy (</offsets><italic><offsets xml_i="27019" xml_f="27020" txt_i="17802" txt_f="17803">P</offsets></italic><offsets xml_i="27029" xml_f="27181" txt_i="17803" txt_f="17952"> &gt; 0.05). However, the posttherapeutic endometrial thickness decreased significantly compared with the pretherapeutic level in all the three groups (</offsets><italic><offsets xml_i="27189" xml_f="27190" txt_i="17952" txt_f="17953">P</offsets></italic><offsets xml_i="27199" xml_f="27323" txt_i="17953" txt_f="18074"> &lt; 0.05), while there was no significant difference in the posttherapeutic endometrial thickness among the three groups (</offsets><italic><offsets xml_i="27331" xml_f="27332" txt_i="18074" txt_f="18075">P</offsets></italic><offsets xml_i="27341" xml_f="27380" txt_i="18075" txt_f="18111"> &gt; 0.05). The results were shown in </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="27410" xml_f="27418" txt_i="18111" txt_f="18119">Figure 4</offsets></xref><offsets xml_i="27425" xml_f="27426" txt_i="18119" txt_f="18120">.</offsets></p><fig id="F4" position="float"><label><offsets xml_i="27467" xml_f="27475" txt_i="18121" txt_f="18129">Figure 4</offsets></label><caption><p><offsets xml_i="27495" xml_f="27556" txt_i="18129" txt_f="18190">Endometrial thickness (mm) before and after GnRH-a therapy. *</offsets><italic><offsets xml_i="27564" xml_f="27565" txt_i="18190" txt_f="18191">P</offsets></italic><offsets xml_i="27574" xml_f="27661" txt_i="18191" txt_f="18275"> &lt; 0.01 versus the same group before gonadotropin releasing hormone agonist therapy.</offsets></p></caption><graphic xlink:href="CMJ-128-427-g004"></graphic></fig></sec><sec id="sec2-18"><title><offsets xml_i="27761" xml_f="27784" txt_i="18277" txt_f="18300">Adverse reaction events</offsets></title><p><offsets xml_i="27795" xml_f="28433" txt_i="18301" txt_f="18939">No serious adverse reaction was observed in all patients who were involved in this study. A few cases scattered in three different groups showed slight skin rash, headache or other symptoms, which disappeared spontaneously during the therapy period, and was not considered to be treatment-related, these data did not enter the statistical analysis. The study revealed that 3 cases in Kuntai and 8 cases in Tibolone group appeared vaginal bleeding or spotting while 2 and 8 cases respectively breast distending pain. The incidence of the adverse events just mentioned above in Kuntai group was obviously lower than that in Tibolone group (</offsets><italic><offsets xml_i="28441" xml_f="28442" txt_i="18939" txt_f="18940">P</offsets></italic><offsets xml_i="28451" xml_f="28644" txt_i="18940" txt_f="19130"> &lt; 0.05). Both Kuntai and Tibolone group had 3 cases respectively to undergo slight nausea, emesis, or abdominal discomfort, no significant difference was identified between the two groups (</offsets><italic><offsets xml_i="28652" xml_f="28653" txt_i="19130" txt_f="19131">P</offsets></italic><offsets xml_i="28662" xml_f="28832" txt_i="19131" txt_f="19298"> &gt; 0.05). In conclusion, the overall incidence of adverse reaction of group Kuntai (32.0% [8/25]) was significantly lower than that of group Tibolone (72.0% [18/25]) (</offsets><italic><offsets xml_i="28840" xml_f="28841" txt_i="19298" txt_f="19299">P</offsets></italic><offsets xml_i="28850" xml_f="28927" txt_i="19299" txt_f="19373"> &lt; 0.05) (Note: Some patients had two or more kinds of adverse reactions).</offsets></p></sec></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="28989" xml_f="28990" txt_i="19376" txt_f="19377">D</offsets><sc><offsets xml_i="28994" xml_f="29003" txt_i="19377" txt_f="19386">ISCUSSION</offsets></sc></title><p><offsets xml_i="29019" xml_f="29238" txt_i="19387" txt_f="19606">The recurrence feature of EMS is quite prominent, and it has become a commonly used method for preventing the EMS recurrence to employ drugs to inhibit estrogen synthesis, which induces the ectopic endometrial atrophy.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="29272" xml_f="29274" txt_i="19606" txt_f="19608">14</offsets></xref><offsets xml_i="29281" xml_f="29536" txt_i="19608" txt_f="19863">] GnRH-a could effectively inhibit pituitary gonadotropin secretion, leading to a significant decrease of ovarian hormone levels and the atrophy of ectopic endometrium, which might play an important role on the postoperative prevention of EMS recurrence.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="29570" xml_f="29572" txt_i="19863" txt_f="19865">12</offsets></xref><offsets xml_i="29579" xml_f="29997" txt_i="19865" txt_f="20283">] However, long-term use of GnRH-a can cause low estrogen related peri-menopausal symptoms, which is often the main reason for the patients to give up the GnRH-a treatment. Estrogen based âadd-back therapyâ combined with GnRH-a administration was proposed to maintain the EMS therapeutic effect after operation, improve the adherence and compliance to GnRH-a treatment, and prolong the treatment time by the scholars.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="30030" xml_f="30031" txt_i="20283" txt_f="20284">1</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="30071" xml_f="30072" txt_i="20284" txt_f="20285">6</offsets></xref><offsets xml_i="30079" xml_f="30357" txt_i="20285" txt_f="20563">] Tibolone is a synthetic steroid hormone preparation, the metabolic products of 3Î±-OH and 3Î²-OH derivatives, with estrogenic activity, can relieve hot flash, night sweat and other low estrogen related symptoms. Currently, Tibolone has been widely used in EMS add-back therapy.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="30391" xml_f="30393" txt_i="20563" txt_f="20565">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="30434" xml_f="30436" txt_i="20565" txt_f="20567">16</offsets></xref><offsets xml_i="30443" xml_f="31210" txt_i="20567" txt_f="21334">] However, as a kind of Chinese Traditional Medicine, the efficacy and safety of Kuntai capsule on peri-menopausal symptoms induced by GnRH-a therapy are not yet entirely clear, which need to be confirmed by the further studies. This study was designed to compare the clinical efficacy and safety of Kuntai capsule with Tibolone in therapy for peri-menopausal symptoms induced by the postoperative GnRH-a treatment in EMS patients. The results revealed that peri-menopausal symptoms appeared in the three groups of patients with GnRH-a injection. In the groups of Kuntai capsule or Tibolone, the total KMI and hot flash/sweating scores decreased gradually after therapy, while in Control group the total KMI and hot flash/sweating scores increased gradually. At the 4</offsets><sup><offsets xml_i="31215" xml_f="31217" txt_i="21334" txt_f="21336">th</offsets></sup><offsets xml_i="31223" xml_f="31373" txt_i="21336" txt_f="21480"> week after GnRH-a injection, KMI and hot flash/sweating scores results were as follows: Control group &gt; Kuntai group &gt; Tibolone group; at the 8</offsets><sup><offsets xml_i="31378" xml_f="31380" txt_i="21480" txt_f="21482">th</offsets></sup><offsets xml_i="31386" xml_f="31393" txt_i="21482" txt_f="21489"> and 12</offsets><sup><offsets xml_i="31398" xml_f="31400" txt_i="21489" txt_f="21491">th</offsets></sup><offsets xml_i="31406" xml_f="32001" txt_i="21491" txt_f="22086"> week after GnRH-a injection, KMI and hot flash/sweating scores in control group were significantly higher than that of Kuntai and Tibolone groups, and no significant difference was identified between Kuntai and Tibolone groups. These results showed that both Kuntai capsule and Tibolone could effectively relieve peri-menopausal symptoms induced by the postoperative GnRH-a treatment in EMS patients. However, the clinical effect of Kuntai capsule might appear a little later than the conventional dose (daily 2.5 mg) of Tibolone, which might be connected with the relatively mild clinical effi</offsets></p><p><offsets xml_i="32008" xml_f="32204" txt_i="22087" txt_f="22283">It was indicated that the effect of Kuntai capsule on peri-menopausal symptoms might be related to the estrogenic activity of the ingredients of Radix Rehmanniae Preparata and Radix Paeoniaealba.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="32238" xml_f="32240" txt_i="22283" txt_f="22285">17</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="32281" xml_f="32283" txt_i="22285" txt_f="22287">18</offsets></xref><offsets xml_i="32290" xml_f="32417" txt_i="22287" txt_f="22414">] Studies revealed that Kuntai capsule could increase the E2 level, and make the vaginal cell maturation index right-shifting.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="32451" xml_f="32453" txt_i="22414" txt_f="22416">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="32494" xml_f="32496" txt_i="22416" txt_f="22418">20</offsets></xref><offsets xml_i="32503" xml_f="32527" txt_i="22418" txt_f="22442">] The research of Zhang </offsets><italic><offsets xml_i="32535" xml_f="32540" txt_i="22442" txt_f="22447">et al</offsets></italic><offsets xml_i="32549" xml_f="32551" txt_i="22447" txt_f="22449">.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="32585" xml_f="32587" txt_i="22449" txt_f="22451">21</offsets></xref><offsets xml_i="32594" xml_f="32830" txt_i="22451" txt_f="22687">] demonstrated that in climacteric rat models, Kuntai capsule could elevate ovarian volume, increase uterine wet weight, improve ovarian function, and nourish uterus, but did not cause local stimulatory effects on the endometrium. Chen </offsets><italic><offsets xml_i="32838" xml_f="32843" txt_i="22687" txt_f="22692">et al</offsets></italic><offsets xml_i="32852" xml_f="32855" txt_i="22692" txt_f="22695">.,[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="32889" xml_f="32891" txt_i="22695" txt_f="22697">22</offsets></xref><offsets xml_i="32898" xml_f="33407" txt_i="22697" txt_f="23206">] employed Kuntai capsule on the menopausal transition and postmenopausal patients. The results showed that Kuntai capsule could alleviate climacteric symptoms effectively in these patients, and had more obvious efficacy on the patients in menopausal transition period, indicating that the treatment effects of Kuntai capsule on menopausal syndrome might be associated with the improvement of ovarian function, bringing the benefit of the absence of E2-like adverse reaction in Kuntai capsule. Cheng and Wang[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="33441" xml_f="33443" txt_i="23206" txt_f="23208">23</offsets></xref><offsets xml_i="33450" xml_f="33804" txt_i="23208" txt_f="23562">] had reported some molecular mechanisms about Kuntai capsule. They found that Kuntai capsule could increase the peripheral serum mRNA and protein expression of estrogen receptor Î± and Î² in peri-menopausal patients, and their research indicated that Kuntai capsule exerted its effects by several different routes, not only by regulating endocrine system.</offsets></p><p><offsets xml_i="33811" xml_f="35254" txt_i="23563" txt_f="25006">In order to further explore the safety profile, this study compared the following factorsâ variations before and after the treatment of Kuntai capsule or Tibolone, including liver and renal functions, lipid profile, serum sex hormone levels, and endometrial thickness. Compared with the pretherapeutic level, no statistical change took place in the liver and renal functions, and lipid profile in all the three groups after the treatment. However, the levels of E2, FSH, and LH as well as endometrial thickness decreased significantly after therapy, which was mainly due to the effective inhibition of pituitary gonadotropin secretion by GnRH-a, reducing ovarian secretion of sex hormone drastically. By comparison with Tibolone group, the post-therapeutic E2 levels in Kuntai and Control groups were significantly lower, while FSH and LH levels were higher. These results revealed that, short-term use of Kuntai capsule or Tibolone had no obvious influence on patientsâ liver and renal functions, as well as serum lipid metabolism, and Kuntai capsule had no obvious estrogenic effects. In terms of adverse reactions, certain superiority and advantages were reflected in Kuntai group. The incidence of vaginal bleeding or spotting, and breast distending pain in Kuntai group were significantly lower than that in Tibolone. The overall incidence of adverse reactions of Kuntai group was significantly lower, similar with some previous results.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="35287" xml_f="35288" txt_i="25006" txt_f="25007">9</offsets></xref><xref rid="ref24" ref-type="bibr"><offsets xml_i="35329" xml_f="35331" txt_i="25007" txt_f="25009">24</offsets></xref><offsets xml_i="35338" xml_f="36219" txt_i="25009" txt_f="25890">] In summary, the postoperative GnRH-a administration in EMS patients would lead to peri-menopausal symptoms related to estrogen deficiency, which could be effectively alleviated by Kuntai capsule and Tibolone. Although the clear clinical effect of Kuntai capsule might appear a little later than Tibolone tablet, maybe this indicates that Kuntai capsule should be administrated much earlier, even before the GnRH-a injection for EMS patients. Kuntai capsule had no obvious impact on patientsâ liver and renal functions as well as blood lipid metabolism. It might be a safe and effective treatment option especially for the patients with hormone contraindications. Both Kuntai capsule and Tibolone could be successfully applied to the âadd-back therapyâ for GnRH-a injection in EMS patients, and Kuntai capsule might be a little safer as it had a lower incidence of adverse events.</offsets></p><p><offsets xml_i="36226" xml_f="36573" txt_i="25891" txt_f="26238">However, this study was based on 75 subjects from two hospitals. The relatively small population size might have limited the statistical power of the detected associations. Future research involving more subjects from multi healthy centers should be performed, and more efforts should be put into the experimental research on molecular mechanisms.</offsets></p></sec></body><back><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Li-Min Chen</p></fn><fn fn-type="supported-by"><p><bold>Source of Support:</bold> This work was supported by a grant from Changzhou Medical Innovative Youth Personnel Project (Changzhou Health and Science [2010] No. 368 KY201139).</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunselman</surname><given-names>GA</given-names></name><name><surname>Vermeulen</surname><given-names>N</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Calhaz-Jorge</surname><given-names>C</given-names></name><name><surname>DâHooghe</surname><given-names>T</given-names></name><name><surname>De Bie</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>ESHRE guideline: Management of women with endometriosis</article-title><source>Hum Reprod</source><year>2014</year><volume>29</volume><fpage>400</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">24435778</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>YJ</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Lang</surname><given-names>JH</given-names></name><name><surname>Leng</surname><given-names>JH</given-names></name></person-group><article-title>Morphological analysis on adhesion and invasion involved in endometriosis with tissue culture</article-title><source>Chin Med J</source><year>2011</year><volume>124</volume><fpage>148</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21362323</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Leng</surname><given-names>JH</given-names></name><name><surname>Lang</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name></person-group><article-title>Anatomical distribution of pelvic deep infiltrating endometriosis and its relationship with pain symptoms</article-title><source>Chin Med J</source><year>2012</year><volume>125</volume><fpage>209</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22340547</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>XN</given-names></name><name><surname>Wei</surname><given-names>ML</given-names></name><name><surname>Tong</surname><given-names>XM</given-names></name><name><surname>Xu</surname><given-names>WH</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>QX</given-names></name><etal></etal></person-group><article-title>Outcome of <italic>in vitro</italic> fertilization in endometriosis-associated infertility: A 5-year database cohort study</article-title><source>Chin Med J</source><year>2012</year><volume>125</volume><fpage>2688</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">22931976</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>KN</given-names></name><name><surname>Kitajima</surname><given-names>M</given-names></name><name><surname>Hiraki</surname><given-names>K</given-names></name><name><surname>Fujishita</surname><given-names>A</given-names></name><name><surname>Nakashima</surname><given-names>M</given-names></name><name><surname>Ishimaru</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma</article-title><source>Hum Reprod</source><year>2010</year><volume>25</volume><fpage>2878</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">20829343</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>JH</given-names></name><name><surname>Lang</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>JX</given-names></name></person-group><article-title>Progress of diagnosis and treatment of endometriosis (in Chinese)</article-title><source>Chin J Obstet Gynecol</source><year>2000</year><volume>35</volume><fpage>53</fpage><lpage>5</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebbeck</surname><given-names>TR</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Norman</surname><given-names>S</given-names></name><name><surname>Bunin</surname><given-names>GR</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>Baumgarten</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A retrospective case-control study of the use of hormone-related supplements and association with breast cancer</article-title><source>Int J Cancer</source><year>2007</year><volume>120</volume><fpage>1523</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17205521</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PS</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>HL</given-names></name><name><surname>Sun</surname><given-names>YL</given-names></name></person-group><article-title>Ximingting tablets in the treatment of women with climacteric syndrome (in Chinese)</article-title><source>J Shandong Univ Med</source><year>2008</year><volume>46</volume><fpage>791</fpage><lpage>4</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>WJ</given-names></name><name><surname>Xu</surname><given-names>LZ</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>LL</given-names></name><name><surname>Zhou</surname><given-names>LL</given-names></name><etal></etal></person-group><article-title>Effects of Kuntai Capsule and hormone replacement therapy on cognitive function and mental symptoms of early postmenopausal women: A randomized controlled trial (in Chinese)</article-title><source>Chin J Integr Med</source><year>2010</year><volume>8</volume><fpage>321</fpage><lpage>7</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Clinical observation of Kuntai capsule on peri-menopausal symptoms (in Chinese)</article-title><source>Tianjin Pharmacol</source><year>2010</year><volume>22</volume><fpage>34</fpage><lpage>5</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>SQ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Luan</surname><given-names>YQ</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Chai</surname><given-names>LN</given-names></name><etal></etal></person-group><article-title>A randomized, multi-center, double blind and parallel controlled clinical trial for Kuntai capsules in the treatment of climacteric syndromes (in Chinese)</article-title><source>Chin J New Drugs</source><year>2005</year><volume>14</volume><fpage>1472</fpage><lpage>6</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almassinokiani</surname><given-names>F</given-names></name><name><surname>Mehdizadeh</surname><given-names>A</given-names></name><name><surname>Sariri</surname><given-names>E</given-names></name><name><surname>Rezaei</surname><given-names>M</given-names></name><name><surname>Almasi</surname><given-names>A</given-names></name><name><surname>Akbari</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Effects of simvastatin in prevention of pain recurrences after surgery for endometriosis</article-title><source>Med Sci Monit</source><year>2013</year><volume>19</volume><fpage>534</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23828228</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wuttke</surname><given-names>W</given-names></name><name><surname>Raus</surname><given-names>K</given-names></name><name><surname>Gorkow</surname><given-names>C</given-names></name></person-group><article-title>Efficacy and tolerability of the black cohosh (<italic>Actaea racemosa</italic>) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo-and conjugated estrogens-controlled study</article-title><source>Maturitas</source><year>2006</year><volume>55</volume><fpage>83</fpage><lpage>91</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nirgianakis</surname><given-names>K</given-names></name><name><surname>Bersinger</surname><given-names>NA</given-names></name><name><surname>McKinnon</surname><given-names>B</given-names></name><name><surname>Kostov</surname><given-names>P</given-names></name><name><surname>Imboden</surname><given-names>S</given-names></name><name><surname>Mueller</surname><given-names>MD</given-names></name></person-group><article-title>Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2013</year><volume>170</volume><fpage>550</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23993133</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>YZ</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>GnRHagonist and add-back therapy with low dose tibolone in the treatment of endometriosis (in Chinese)</article-title><source>Prog Obstet Gynecol</source><year>2003</year><volume>12</volume><fpage>120</fpage><lpage>3</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>W</given-names></name><name><surname>Henneicke-von Zepelin</surname><given-names>HH</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone</article-title><source>Maturitas</source><year>2007</year><volume>58</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17587516</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>P</given-names></name></person-group><article-title>Clinical observation of Kuntai capsule on climacteric syndrome (in Chinese)</article-title><source>J Tradit Chin Med</source><year>2002</year><volume>43</volume><fpage>258</fpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SH</given-names></name><name><surname>Sun</surname><given-names>JF</given-names></name><name><surname>Guo</surname><given-names>SZ</given-names></name></person-group><article-title>Effect of compound recipe Gengniankang on senile sexual hormone and expression of estrogen receptor in bone of climacteric female rats (in Chinese)</article-title><source>Chin J Integr Med</source><year>2005</year><volume>11</volume><fpage>205</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16181536</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>JL</given-names></name></person-group><article-title>The efficacy investigation of Kuntai capsule on climacteric syndrome (in Chinese)</article-title><source>Chin J Integr Med</source><year>2002</year><volume>43</volume><fpage>255</fpage><lpage>6</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>QW</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name></person-group><article-title>The clinical efficacy investigation of Kuntai capsule on climacteric syndrome (in Chinese)</article-title><source>J Tradit Chin Med</source><year>2002</year><volume>43</volume><fpage>264</fpage><lpage>5</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SF</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Bi</surname><given-names>CP</given-names></name><name><surname>Zhu</surname><given-names>HT</given-names></name><name><surname>Ha</surname><given-names>LX</given-names></name><etal></etal></person-group><article-title>Effects of gengnianningxin capsule on the histomorphology of ovarin and uterine in the menopausal rats (in Chinese)</article-title><source>Chin J Geriatr</source><year>2004</year><volume>23</volume><fpage>648</fpage><lpage>52</lpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>SQ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Luan</surname><given-names>YQ</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>DM</given-names></name></person-group><article-title>Effects of Kuntai capsule and estradiol valerate on different symptoms of climacteric syndrome (in Chinese)</article-title><source>Med Rev</source><year>2013</year><volume>19</volume><fpage>1869</fpage><lpage>72</lpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>FR</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Effects of Kuntai capsule on estrogen and ER expression of patients with peri-menopausalsyndrome (in Chinese)</article-title><source>Chin Arch Tradit Chin Med</source><year>2014</year><volume>32</volume><fpage>2279</fpage><lpage>82</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>LL</given-names></name><name><surname>Zhang</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Effects of Kuntai capsule on quality of life, breast distending pain and vaginal bleeding in women at early stage of menopause (in Chinese)</article-title><source>Chin J Integr Med</source><year>2008</year><volume>28</volume><fpage>972</fpage><lpage>6</lpage></element-citation></ref></ref-list></back></article>